| scholarly article | Q13442814 |
| P50 | author | Bo Ahrén | Q5544506 |
| P2093 | author name string | Anja Schweizer | |
| Giovanni Pacini | |||
| James E Foley | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| cell function | Q95674809 | ||
| patient | Q181600 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 1936-1940 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year | |
| P478 | volume | 28 |
| Q38282880 | A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy |
| Q37237442 | Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes |
| Q53746829 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. |
| Q45250947 | Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes |
| Q26749089 | An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass |
| Q26829445 | Assessment of pancreatic β-cell function: review of methods and clinical applications |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q36575421 | Biologic actions and therapeutic potential of the proglucagon-derived peptides |
| Q33587783 | Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspective |
| Q37825941 | Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin |
| Q37984567 | Clinical pharmacokinetics and pharmacodynamics of vildagliptin |
| Q38106411 | Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. |
| Q37991385 | Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. |
| Q36835802 | Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet |
| Q37056847 | Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin |
| Q91638366 | DPP-4 Inhibition and the Path to Clinical Proof |
| Q27028127 | DPP-4 inhibition and islet function |
| Q36729115 | DPPIV inhibition: promising therapy for the treatment of type 2 diabetes |
| Q43207763 | Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload |
| Q49997164 | Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes |
| Q34589793 | Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. |
| Q36892807 | Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus |
| Q37900690 | Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence |
| Q30846870 | Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis |
| Q35026483 | Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy |
| Q37378498 | Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema |
| Q55518630 | Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial. |
| Q42496887 | Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes |
| Q51444165 | Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study. |
| Q37439806 | Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog |
| Q35442079 | Effect of vildagliptin on hepatic steatosis |
| Q64902975 | Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in "Real-World" Management of Type 2 Diabetes Mellitus: The G-FORCE Study. |
| Q38832851 | Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting |
| Q46567048 | Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus |
| Q36315963 | Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials |
| Q38077284 | Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis |
| Q45985301 | Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes. |
| Q37153711 | Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study |
| Q51281907 | Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) |
| Q51489068 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. |
| Q34044817 | Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study |
| Q51478128 | Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. |
| Q42955206 | Electrical stimulation of the isolated rat intestine in the presence of nutrient stimulus enhances glucagon-like peptide-1 release |
| Q46121472 | Expanding treatment options for type 2 diabetes: the old and the new. |
| Q46637836 | GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide |
| Q37071183 | Glucokinase activators in diabetes management |
| Q36729110 | Hit and Lead identification: efficient practices for drug discovery |
| Q36640585 | How do different GLP-1 mimetics differ in their actions? |
| Q46140543 | Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes |
| Q48277301 | Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study |
| Q53272501 | Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy. |
| Q35928257 | Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism |
| Q38225693 | Incretins: their physiology and application in the treatment of diabetes mellitus. |
| Q36580608 | Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes |
| Q42477903 | Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin |
| Q27649728 | Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation |
| Q36613938 | Management of Type 2 diabetes: the role of incretin mimetics |
| Q24683764 | Mechanisms of action of glucagon-like peptide 1 in the pancreas |
| Q37867193 | Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans |
| Q37941683 | Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus |
| Q37262966 | Metformin therapy and clinical uses |
| Q37183979 | More choices than ever before: emerging therapies for type 2 diabetes |
| Q100526083 | Neopterin and biopterin levels and tryptophan degradation in patients with diabetes |
| Q39626084 | New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser |
| Q37288741 | New drugs for type 2 diabetes mellitus: what is their place in therapy? |
| Q36812821 | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
| Q51323275 | Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy. |
| Q34592210 | Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes |
| Q37260330 | Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. |
| Q58448401 | Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT |
| Q36793605 | Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents |
| Q34139048 | Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment |
| Q36960161 | Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability |
| Q36693199 | Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus |
| Q24235718 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24240522 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24244739 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q34128612 | Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data |
| Q40524112 | Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). |
| Q38071007 | Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors |
| Q91991896 | Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes |
| Q26772081 | Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors |
| Q38682317 | Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. |
| Q37270524 | Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors |
| Q37782506 | Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus |
| Q36945116 | The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond |
| Q88312476 | The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration |
| Q48713671 | The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: Effects on peripheral sensory nerve function, structure and molecular changes |
| Q35688754 | The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions |
| Q28273497 | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes |
| Q34329204 | The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives |
| Q35333042 | The metabolic serine hydrolases and their functions in mammalian physiology and disease |
| Q53242373 | The physiology of incretin hormones and the basis for DPP-4 inhibitors. |
| Q42575070 | The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus |
| Q36800624 | The role of vildagliptin in the management of type 2 diabetes mellitus |
| Q37840099 | The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease |
| Q34750027 | Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass. |
| Q42010899 | Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus |
| Q42171281 | Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors |
| Q37161925 | Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents |
| Q37857686 | Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin |
| Q36651661 | Vildagliptin |
| Q37623831 | Vildagliptin in clinical practice: a review of literature. |
| Q37428878 | Vildagliptin: a new oral treatment for type 2 diabetes mellitus |
| Q36847177 | Vildagliptin: a novel oral therapy for type 2 diabetes mellitus |
| Q37313418 | Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. |
| Q87461871 | Vildagliptin: a review of its use in type 2 diabetes mellitus |
| Q37801906 | Vildagliptin: a review of its use in type 2 diabetes mellitus |
| Q33973990 | Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus |
| Q34068749 | Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience |
| Q48269534 | When Metformin Is Not Enough: Pros and Cons of SGLT2 and DPP-4 Inhibitors as a Second Line Therapy |
| Q80204033 | [New approaches in obesity treatment: the gastrointestinal tract as an endocrine organ] |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
Search more.